Zanubrutinib maintenance therapy for DLBCL in remission
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 trial studies zanubrutinib taken after your DLBCL (a type of lymphoma) goes into remission, to help keep it controlled for longer. It focuses on people who have higher-risk features and can safely take this medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older with DLBCL confirmed by standard guidelines
- You are currently in initial remission and have not received other treatment yet
- You have measurable disease on scans (enlarged lymph nodes or outside the lymph nodes)
- Your health status is good enough (ECOG 0 to 2) and you fall into an intermediate-high or high-risk group
- Your tumor must show certain lab/genetic markers (MYC, BCL-2, BCL-6 or MYD88/CD79A/CD79B plus TP53 changes)
- Your blood counts and organ tests are within required safety ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This trial tests a maintenance therapy with zanubrutinib in newly diagnosed DLBCL patients who have responded to initial treatment but couldn't tolerate standard chemotherapy. The goal is to prevent the cancer from coming back.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
Hear when a new Diffuse Large B-cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.